Orthocell unveils first clinical trial results for nerve regeneration platform CelGro
Regenerative medicine company Orthocell (ASX: OCC) has provided the first batch of evidence supporting the efficacy of its CelGro nerve regeneration platform.
The company published results of the first four patients to complete the clinical trial using CelGro, with patients experiencing an 83% improvement in muscle power.
The trial is ongoing and undertaken in association with leading West Australian orthopaedic nerve specialist, Dr Alex O’Beirne of St John of God Subiaco Hospital and Professor Ming Hao Zheng of the University of Western Australia.
Orthocell said it conducted the trial to demonstrate the effectiveness of CelGro and confirm that the platform can be used to guide and promote “tensionless nerve regeneration in damaged peripheral nerves of the hand and upper limb”.
If successfully proven, Orthocell plans to market its CelGro platform in Europe and other major markets globally. In the US, alone, over 20 million people suffer from peripheral nerve injury as a result of acute muscle injuries every year, at an annual cost of approximately US$150 billion (A$213 billion).More…